GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Cash Flow from Financing

Lin BioScience (ROCO:6696) Cash Flow from Financing : NT$2,636.91 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2023, Lin BioScience received NT$11.59 Mil more from issuing new shares than it paid to buy back shares. It received NT$0.00 Mil from issuing more debt. It paid NT$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received NT$0.00 Mil from paying cash dividends to shareholders. It received NT$684.25 Mil on other financial activities. In all, Lin BioScience earned NT$695.85 Mil on financial activities for the six months ended in Jun. 2023.


Lin BioScience Cash Flow from Financing Historical Data

The historical data trend for Lin BioScience's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Cash Flow from Financing Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial 57.56 1,160.36 28.32 1,129.79 2,636.91

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.35 1,120.83 8.97 690.64 1,946.27

Lin BioScience Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Lin BioScience's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Lin BioScience's Cash from Financing for the quarter that ended in Jun. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$2,636.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lin BioScience  (ROCO:6696) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Lin BioScience's issuance of stock for the six months ended in Jun. 2023 was NT$11.59 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Lin BioScience's repurchase of stock for the six months ended in Jun. 2023 was NT$0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Lin BioScience's net issuance of debt for the six months ended in Jun. 2023 was NT$0.00 Mil. Lin BioScience received NT$0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Lin BioScience's net issuance of preferred for the six months ended in Jun. 2023 was NT$0.00 Mil. Lin BioScience paid NT$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Lin BioScience's cash flow for dividends for the six months ended in Jun. 2023 was NT$0.00 Mil. Lin BioScience received NT$0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Lin BioScience's other financing for the six months ended in Jun. 2023 was NT$684.25 Mil. Lin BioScience received NT$684.25 Mil on other financial activities.


Lin BioScience Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines